|James Chang Ph.D.||CEO, Pres & Director||N/A||N/A||N/A|
|Dr. David D. Ho||Scientific Co-Founder, Chief Scientific Advisor and Board Director||N/A||N/A||N/A|
|Dr. Ing-Wen Tsai Ph.D.||Co-Founder||N/A||N/A||N/A|
|Dr. Lan-Bo Chen Ph.D.||Co-Founder||N/A||N/A||N/A|
|Jack Chen||Chief Financial Officer||N/A||N/A||N/A|
TaiMed Biologics Inc., a biotechnology company, develops health-care products. The company develops and markets TMB-355, a humanized monoclonal antibody intravenous infusion for the treatment of HIV-1 infection. It is also developing TMB-355, a humanized monoclonal antibody intramuscular injection, which is in Phase II clinical trial for treating HIV/AIDS; TMB-607, a novel HIV-1 protease inhibitor that is in Phase I clinical trial; TMB-365, an anti-CD4 recombinant humanized monoclonal antibody, which is in Phase I clinical trial for treating HIV infections; TMB-Bispecific, a bispecific neutralizing antibody that is in Phase I clinical trial to treat HIV infections; and TMB-ADC, an antibodydrug conjugate for treating HIV infection. The company was founded in 2007 and is based in Taipei City, Taiwan.
TaiMed Biologics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.